Printer friendly

What does ACE stand for?

ACE stands for Ang I)-converting enzyme


This definition appears rarely

See other definitions of ACE

Other Resources: Acronym Finder has 373 verified definitions for ACE

Samples in periodicals archive:

Angiotensin-converting enzyme inhibitors were developed as therapeutic agents targeted for the treatment of hypertension. Since the initial application of these agents, several additional clinical indications have been identified and approved. This review summarizes the pharmacology of ACE inhibitors and their current clinical indications.
Angiotensin converting enzyme (ACE) inhibitors are now one of the most frequently used classes of antihypertensive drugs. Beyond their utility in the management of hypertension, their use has been extended to the long-term management of patients with congestive heart failure (CHF), as well as diabetic and nondiabetic nephropathies. Although ACE inhibitor therapy usually improves renal blood flow (RBF) and sodium excretion rates in CHF and reduces the rate of progressive renal injury in chronic renal disease, its use can also be associated with a syndrome of “functional renal insufficiency” and/or hyperkalemia.
Title: Association of polymorphisms of angiotensin I converting enzyme.
It is believed that treatment with an ARB increases the level of plasma angiotensin II (Ang II) because of a lack of negative feedback on renin activity. However, Ichikawa (Hypertens Res 2001; 24: 641–646) reported that long-term treatment of hypertensive patients with olmesartan resulted in a reduction in plasma Ang II level, though the mechanism was not determined. It has been reported that angiotensin 1-7 (Ang-(1-7)) potentiates the effect of bradykinin and acts as an angiotensin-converting enzyme.
Most results confirmed that the ACEI and ARB combination therapy induced a slight improvement in hypertension control [4] and a definite reduction of proteinuria if concomitant renal damage was present [8,9]. However, increased incidences of hypotensive episodes [6,7], moderate to severe hyperkalemia [7] and adverse renal outcomes [2], the latter primarily reported in patients without proteinuria; have led to a reconsideration of the balance between the risks (increases of serum creatinine) and benefits (reductions of proteinuria) of the ACEI and ARB combination therapy. Renal side-effects, such as hyperkalemia and excessive reduction of the glomerular filtration rate, as well as potentially worse complications, such as acute renal failure, have to be further and more systematically evaluated. Thus, caution is advisable in the administration of this combination therapy until results from several ongoing trials with specific renal endpoints (Design of combination angiotensin receptor blocker and angiotensin-converting enzyme.
Pomegranate juice reduces blood pressure by inhibiting Angiotensin Converting Enzyme.